Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2020; 12(11): 1020-1030
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1020
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1020
Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma
Tomoki Sempokuya, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States
Eric A Wien, Robert J Pattison, Department of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, United States
Jihyun Ma, Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, United States
Linda L Wong, Department of Surgery, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96817, United States
Author contributions: Sempokuya T contributed to study design, data collection, statistical analysis; Sempokuya T, Wien E and Pattison R contributed to the literature review, manuscript drafting, and editing; Ma J contributed to study design and statistical analysis; Wong L contributed to study supervision, manuscript drafting and editing; and all of the authors approved the final version of the manuscript.
Institutional review board statement: Since we utilized publicly available de-identified database, review by our institutional review board was not required.
Informed consent statement: Informed consent was not required to conduct this study.
Conflict-of-interest statement: LW is a speaker bureau for Eisai. Other authors do not have any conflict of interest.
Data sharing statement: All the data used in this analysis is available from SEER database.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tomoki Sempokuya, MD, Doctor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, 982000 Nebraska Medical Center, Omaha, NE 68198, United States. tsempoku@hawaii.edu
Received: April 15, 2020
Peer-review started: April 15, 2020
First decision: June 4, 2020
Revised: July 25, 2020
Accepted: October 12, 2020
Article in press: October 12, 2020
Published online: November 27, 2020
Processing time: 222 Days and 23.7 Hours
Peer-review started: April 15, 2020
First decision: June 4, 2020
Revised: July 25, 2020
Accepted: October 12, 2020
Article in press: October 12, 2020
Published online: November 27, 2020
Processing time: 222 Days and 23.7 Hours
Core Tip
Core Tip: Combined hepatocellular and cholangiocarcinoma (HCC/CC) is a rare primary hepatic malignancy which carries a poor prognosis due to its aggressive nature. Few centers have enough cases to draw definitive conclusions and there is limited understanding of prognosis. This analysis of Surveillance, Epidemiology, and End Results database comprised of 497 patients. HCC/CC patients with tumor size < 50 mm, resection, and transplant were associated with an increase in 5-year survival. Asian and Pacific Islander (API) showed advantageous odds ratios and hazard ratios over white, black. Elucidation of better prognosis on API are needed in the future studies.